Nasdaq1mnd
Daré Bioscience Initiates Phase 3 Study for Sildenafil Cream as Potential First FDA-Approved Treatment for Female Sexual Arousal Disorder
If successful, Sildenafil Cream could become the first FDA-approved treatment for FSAD, addressing a significant unmet need in women's sexual health. The company plans to submit the study protocol ...
Things You Probably Don't Know About Viagra (Like What It Was Originally Used For)
Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...
Yahoo Finance1mnd
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates ...
Is Sildenafil Safe for This Common Male Problem?
In the ‘80s, researchers set out to test a medication called sildenafil citrate for treating high blood pressure and angina ...
Yahoo Finance1mnd
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA ...
urologytimes1mnd
Efficacy of sildenafil cream for FSAD maintained across patient subgroups
no pharmacologic options have yet been FDA approved for FSAD, a condition which significantly compromises a woman's ability to have a pleasurable sexual experience. We are excited about the potential ...
The Globe and Mail1mnd
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.